Breaking News

Northwest Bio, Advent BioServices Gain MHRA License for Commercial Manufacturing

Gains authorization for commercial manufacturing of cell therapy products at the GMP facility in Sawston.

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, and Advent BioServices, a contract development and manufacturing organization (CDMO) based in the UK, jointly announce that a manufacturer’s importation authorization (MIA) license has been approved and issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) for commercial manufacturing of cell therapy products at the GMP facility in Sawston, UK. Accordin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters